Last update 29 May 2025

XENON XE 129 hyperpolarized

Overview

Basic Info

Drug Type
Contrast agent, Chemical drugs
Synonyms
129Xe, Hyperpolarized 129-Xenon, hyperpolarized xenon Xe 129
+ [1]
Target-
Action
enhancers
Mechanism
Magnetic resonance imaging enhancers
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (23 Dec 2022),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaXe
InChIKeyFHNFHKCVQCLJFQ-YPZZEJLDSA-N
CAS Registry13965-99-6

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Contrast agents
United States
23 Dec 2022
Lung Diseases
United States
23 Dec 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Connective Tissue DiseasesPhase 2
United States
12 Aug 2024
Connective Tissue DiseasesPhase 2
United States
12 Aug 2024
Idiopathic pulmonary arterial hypertensionPhase 2
United States
12 Aug 2024
Idiopathic pulmonary arterial hypertensionPhase 2
United States
12 Aug 2024
Pulmonary arterial hypertension associated with connective tissue diseasePhase 2
United States
12 Aug 2024
Pulmonary arterial hypertension associated with connective tissue diseasePhase 2
United States
12 Aug 2024
Pulmonary Arterial HypertensionPhase 2--15 Mar 2024
AnemiaPhase 2
United States
12 Jan 2024
Chronic thromboembolic pulmonary hypertensionPhase 2
United States
12 Jan 2024
DyspneaPhase 2
United States
12 Jan 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
38
129Xe MRI
mfkbvwrgtg(xwwujoreik) = dlyzznegtd cysbljpoul (opwbaeyybg, 2.88)
-
28 Jun 2022
Not Applicable
-
-
(Gas exchange-optimized plans)
sweoehpzpj(teopvvvrpu) = roruomdgya wlklewxkcv (fqvqmdajde, 45)
-
01 Nov 2020
(Ventilation-optimized plans)
sweoehpzpj(teopvvvrpu) = uzqxolqpph wlklewxkcv (fqvqmdajde, 31)
Not Applicable
33
ugjvmuzpsm(betfjxinxp) = qlzimmsdqn pehegpjvjf (bgurregdrr )
-
28 Sep 2019
ugjvmuzpsm(betfjxinxp) = feaysquaet pehegpjvjf (bgurregdrr )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free